SURVYR

CELC

Celcuity Inc.
$68.07
+$2.27 (3.45%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-31%+1%+32%+63%+95%Oct 2025Oct 2026Apr 202652w high $151.0252w low $53.54
CELCSPY
Wall St. Highest PT $177.00 (+160.0%) Wall St. Avg PT $154.69 (+127.3%)
$57$103$149$196$242POC $91Hi $177Avg $155
Underwater Drawdown %Max DD -61.0%Current -53.0%
0.0%-61.0%
Relative Strength vs SPY-25.7% vs SPYUnderperforming
+94%0%-94%
1W
+$8.07 (13.45%)
1M
−$11.45 (14.40%)
3M
−$14.39 (17.45%)
6M
−$52.00 (43.31%)
YTD
−$31.67 (31.75%)
1Y
−$9.44 (12.18%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
13 analysts · mean score 1.23
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$68.07
Average target$154.69
+$86.62 (+127.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$130.00
Median$154.69
High$177.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-22 · Cantor Fitzgerald started covering CELC at Overweight
Reiterated
2026-10-21 · TD Cowen reiterated Buy on CELC
Reiterated
2026-09-30 · Needham reiterated Buy on CELC
Initiated
2026-09-17 · JP Morgan started covering CELC at Overweight
Reiterated
2026-08-17 · Guggenheim reiterated Buy on CELC
Reiterated
2026-08-17 · Citizens reiterated Market Outperform on CELC
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$3.2B
P/E (next 12 months, estimated)-815.6
52-week range$53.54 – $151.02
Dividend yieldNo dividend
Analyst consensusStrong Buy (13)
Average analyst price target$154.69 (+127%)

What they do

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for CELC yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

CELC earningsNext report in 14 days
Next report · quarter Sep 2026
Wed Nov 11, 2026Time not confirmed
EPS consensus-$1.51 range -$1.60–-$1.42
Revenue consensus$1.2M 10 analysts
Last 4 quarters · EPS vs estimate
Aug 13, 2026-$1.07est -$1.08+0.9%In line with estimates
May 14, 2026-$0.86est -$0.89+3.4%Above estimates
Mar 25, 2026-$0.73est -$1.01+27.7%Above estimates
Nov 12, 2025-$0.78est -$0.96+18.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-23 23:32:03 ET
24-1125-0325-0525-0825-1126-0326-0526-08-1.080.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
GlobeNewswire · Oct 23
Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
Investing.com · Oct 22
Netflix downgraded, Tesla upgraded: Wall Street's top analyst calls
The Fly · Oct 22
Cantor Fitzgerald Initiates Celcuity at Overweight With $140 Price Target
MT Newswires · Oct 22
Celcuity (CELC) Stock May Be Hard To Value On Book Value
Simply Wall St. · Oct 18
Rating changes
Initiated
2026-10-22 · Cantor Fitzgerald started covering CELC at Overweight
Reiterated
2026-10-21 · TD Cowen reiterated Buy on CELC
Reiterated
2026-09-30 · Needham reiterated Buy on CELC
Initiated
2026-09-17 · JP Morgan started covering CELC at Overweight
Reiterated
2026-08-17 · Guggenheim reiterated Buy on CELC
Reiterated
2026-08-17 · Citizens reiterated Market Outperform on CELC

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-23 23:32:03 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026